PTC Therapeutics, Inc.
PTCT
Rang in Aktien
#3385
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Aktienkurs
$61.65
Marktkapitalisierung
$5.15B
Veränderung (1 Tag)
4.07%
Veränderung (1 Jahr)
-6.52%
Land
US
Handel PTC Therapeutics, Inc. (PTCT)
Kategorie
Healthcare
Gewinn für PTC Therapeutics, Inc. (PTCT)
Gewinn im Jun 2026 TTM: $-67.07M
Laut den aktuellen Finanzberichten von PTC Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $-67.07M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-696.11M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-587.49M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von PTC Therapeutics, Inc. von 2011 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-67.07M | -81.53% |
| 2024 | $-363.12M | -47.84% |
| 2023 | $-696.11M | 18.49% |
| 2022 | $-587.49M | 13.34% |
| 2021 | $-518.34M | 28.64% |
| 2020 | $-402.93M | 67.94% |
| 2019 | $-239.93M | 87.28% |
| 2018 | $-128.11M | 64.95% |
| 2017 | $-77.67M | -45.13% |
| 2016 | $-141.54M | -16.72% |
| 2015 | $-169.96M | 72.64% |
| 2014 | $-98.45M | 90.88% |
| 2013 | $-51.57M | 96.58% |
| 2012 | $-26.24M | -191.73% |
| 2011 | $28.60M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
